TP53 and ovarian carcinoma: For the clinical trial in NCT04516447 in a study of ZN-c3 in patients with platinum-resistant ovarian cancer, levels of circulating deoxyribonucleic acid TP53 mutations tested by TAm-Seq will be correlated with response and changes in pCDC2 and pH2AX in skin and tumor tissue, which will be evaluated as pharmacodynamic markers of therapy.